{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06318676",
            "orgStudyIdInfo": {
                "id": "CA057-1009"
            },
            "organization": {
                "fullName": "Celgene",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment",
            "officialTitle": "A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide (BMS-986348, CC-92480) in Adult Participants With Normal Renal Function, Severe Renal Impairment, and End-stage Renal Disease",
            "therapeuticArea": [
                "Nephrology and Renal Diseases"
            ],
            "study": "a-study-to-evaluate-the-drug-levels-of-mezigdomide-in-adult-participants-with-renal-impairment"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-12",
            "studyFirstSubmitQcDate": "2024-03-12",
            "studyFirstPostDateStruct": {
                "date": "2024-03-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Celgene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment."
        },
        "conditionsModule": {
            "conditions": [
                "Renal Impairment"
            ],
            "keywords": [
                "Chronic Kidney Disease",
                "End Stage Renal Disease",
                "Dialysis",
                "Hemodialysis",
                "Mezigdomide",
                "Pharmacokinetics",
                "Healthy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group A: Participants with severe renal impairment",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Mezigdomide"
                    ]
                },
                {
                    "label": "Group B: Participants with End Stage Renal Disease",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Mezigdomide"
                    ]
                },
                {
                    "label": "Group C: Participants with normal renal function",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Mezigdomide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Mezigdomide",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Group A: Participants with severe renal impairment",
                        "Group B: Participants with End Stage Renal Disease",
                        "Group C: Participants with normal renal function"
                    ],
                    "otherNames": [
                        "BMS-986348",
                        "CC-92480"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum observed concentration (Cmax)",
                    "timeFrame": "Up to 24 days"
                },
                {
                    "measure": "Area under the plasma concentration-time curve (AUC)",
                    "timeFrame": "Up to 24 days"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC(0-T))",
                    "timeFrame": "Up to 24 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants with adverse events (AEs)",
                    "timeFrame": "Up to 54 days"
                },
                {
                    "measure": "Number of participants with serious adverse events (SAEs)",
                    "timeFrame": "Up to 54 days"
                },
                {
                    "measure": "Number of participants with physical examination findings",
                    "timeFrame": "Up to 24 days"
                },
                {
                    "measure": "Number of participants with vital sign abnormalities",
                    "timeFrame": "Up to 24 days"
                },
                {
                    "measure": "Number of participants with 12-lead electrocardiogram (ECG) findings",
                    "timeFrame": "Up to 24 days"
                },
                {
                    "measure": "Maximum observed concentration (Cmax)",
                    "timeFrame": "Up to 24 days"
                },
                {
                    "measure": "Time of maximum observed concentration (Tmax)",
                    "timeFrame": "Up to 24 days"
                },
                {
                    "measure": "Area under the plasma concentration-time curve (AUC)",
                    "timeFrame": "Up to 24 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n* Participants must have a body mass index (BMI) of \u2265 18.0 kg/m2 to \u2264 40.0 kg/m2 inclusive at screening.\n* Participants must have a body weight \u2265 50 kg at screening.\n* Participants must be afebrile (febrile is defined as \u2265 38\u00b0C or 100.4\u00b0F) at screening, check in, and predose.\n\nExclusion Criteria\n\n* Participants must not have any history of chronic pruritus or dermatologic syndromes that may be confounded with reactions to mezigdomide.\n* Participants must not have any history of malignancy of any type other than in situ cervical cancer or surgically excised non-melanomatous skin cancers.\n* Participants with an inability to tolerate oral medication.\n* Other protocol-defined Inclusion/Exclusion criteria apply.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "82 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect www.BMSStudyConnect.com",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clinical.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain NCT# and Site#",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "PANAX",
                    "status": "RECRUITING",
                    "city": "Miami Lakes",
                    "state": "Florida",
                    "zip": "33014",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Robert Perry, Site 0001",
                            "role": "CONTACT",
                            "phone": "305-698-4500"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.90871,
                        "lon": -80.30866
                    }
                },
                {
                    "facility": "Omega Research Group - Orlando",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32808",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kwabena Ayesu, Site 0003",
                            "role": "CONTACT",
                            "phone": "386-668-4202"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Orlando Clinical Research Center OCRC",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32809",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Thomas Marbury, Site 0002",
                            "role": "CONTACT",
                            "phone": "407-257-3462"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "http://www.fda.gov/MEDWATCH/safety.htm"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "CSR"
            ],
            "timeFrame": "See plan description",
            "accessCriteria": "See plan description",
            "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000051437",
                    "term": "Renal Insufficiency"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M26718",
                    "name": "Renal Insufficiency",
                    "asFound": "Renal Impairment",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10699",
                    "name": "Kidney Failure, Chronic",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}